Transthyretin cardiac amyloidosis
Cardiovascular Research · 03.02.2023 · 118 (18) · 3517-3535
DOI: 10.1093/cvr/cvac119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 05.08.2022. Verfasst von Aldostefano Porcari und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. Hauptthemen laut MEDLINE: Amyloidosis, Cardiomyopathies, Heart Failure. Die Arbeit wurde bisher 171-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Intermediate Clinical Research Fellowship.
Abstract (Originalsprache)
Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a daily basis. Amyloid fibril formation results from age-related failure of homoeostatic mechanisms in wild-type ATTR (ATTRwt) amyloidosis (non-hereditary form) or destabilizing mutations in variant ATTR (ATTRv) amyloidosis (hereditary form). Longitudinal large-scale studies in the United States suggest an incidence of cardiac amyloidosis in the contemporary era of 17 per 100 000, which has increased from a previous estimate of 0.5 per 100 000, which was almost certainly due to misdiagnosis and underestimated. The presence and degree of cardiac involvement is the leading cause of mortality both in ATTRwt and ATTRv amyloidosis, and can be identified in up to 15% of patients hospitalized for HF with preserved ejection fraction. Associated features, such as carpal tunnel syndrome, can preceed by several years the development of symptomatic HF and may serve as early disease markers. Echocardiography and cardiac magnetic resonance raise suspicion of disease and might offer markers of treatment response at a myocardial level, such as extracellular volume quantification. Radionuclide scintigraphy with ‘bone’ tracers coupled with biochemical tests may differentiate ATTR from light chain amyloidosis. Therapies able to slow or halt ATTR-CA progression and increase survival are now available. In this evolving scenario, early disease recognition is paramount to derive the greatest benefit from treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.
- Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste 34149, Italy.
ORCID-Profile: Aldostefano Porcari, Marianna Fontana, Julian D Gillmore
Förderung
- British Heart Foundation
- Intermediate Clinical Research Fellowship
Zitieren
APA
Porcari, A., Fontana, M., & Gillmore, J. D. (2023). Transthyretin cardiac amyloidosis. Cardiovascular Research, 118(18), 3517-3535. https://doi.org/10.1093/cvr/cvac119
Vancouver
Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovascular Research. 2023;118(18):3517-3535. doi:10.1093/cvr/cvac119
BibTeX
@article{Porcari2023,
author = {Porcari, Aldostefano and Fontana, Marianna and Gillmore, Julian D},
title = {Transthyretin cardiac amyloidosis},
journal = {Cardiovascular Research},
year = {2023},
volume = {118},
number = {18},
pages = {3517--3535},
doi = {10.1093/cvr/cvac119}
}
EUVIMED